304 related articles for article (PubMed ID: 33497609)
41. Engineered CRISPR Systems for Next Generation Gene Therapies.
Pineda M; Moghadam F; Ebrahimkhani MR; Kiani S
ACS Synth Biol; 2017 Sep; 6(9):1614-1626. PubMed ID: 28558198
[TBL] [Abstract][Full Text] [Related]
42. Lentivirally transduced dendritic cells as a tool for cancer immunotherapy.
Breckpot K; Dullaers M; Bonehill A; van Meirvenne S; Heirman C; de Greef C; van der Bruggen P; Thielemans K
J Gene Med; 2003 Aug; 5(8):654-67. PubMed ID: 12898635
[TBL] [Abstract][Full Text] [Related]
43. Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity.
He Y; Zhang J; Mi Z; Robbins P; Falo LD
J Immunol; 2005 Mar; 174(6):3808-17. PubMed ID: 15749922
[TBL] [Abstract][Full Text] [Related]
44. Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function.
Shifrut E; Carnevale J; Tobin V; Roth TL; Woo JM; Bui CT; Li PJ; Diolaiti ME; Ashworth A; Marson A
Cell; 2018 Dec; 175(7):1958-1971.e15. PubMed ID: 30449619
[TBL] [Abstract][Full Text] [Related]
45. Current Advance of Immune Evasion Mechanisms and Emerging Immunotherapies in Renal Cell Carcinoma.
Jian Y; Yang K; Sun X; Zhao J; Huang K; Aldanakh A; Xu Z; Wu H; Xu Q; Zhang L; Xu C; Yang D; Wang S
Front Immunol; 2021; 12():639636. PubMed ID: 33767709
[TBL] [Abstract][Full Text] [Related]
46. Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells.
Dong MB; Wang G; Chow RD; Ye L; Zhu L; Dai X; Park JJ; Kim HR; Errami Y; Guzman CD; Zhou X; Chen KY; Renauer PA; Du Y; Shen J; Lam SZ; Zhou JJ; Lannin DR; Herbst RS; Chen S
Cell; 2019 Aug; 178(5):1189-1204.e23. PubMed ID: 31442407
[TBL] [Abstract][Full Text] [Related]
47. Exploiting the CRISPR-Cas9 gene-editing system for human cancers and immunotherapy.
Afolabi LO; Afolabi MO; Sani MM; Okunowo WO; Yan D; Chen L; Zhang Y; Wan X
Clin Transl Immunology; 2021; 10(6):e1286. PubMed ID: 34188916
[TBL] [Abstract][Full Text] [Related]
48. High-throughput screens in mammalian cells using the CRISPR-Cas9 system.
Peng J; Zhou Y; Zhu S; Wei W
FEBS J; 2015 Jun; 282(11):2089-96. PubMed ID: 25731961
[TBL] [Abstract][Full Text] [Related]
49.
Zhou ZP; Yang LL; Cao H; Chen ZR; Zhang Y; Wen XY; Hu J
Hum Gene Ther; 2019 Sep; 30(9):1101-1116. PubMed ID: 31099266
[TBL] [Abstract][Full Text] [Related]
50. Breast cancer vaccines delivered by dendritic cell-targeted lentivectors induce potent antitumor immune responses and protect mice from mammary tumor growth.
Bryson PD; Han X; Truong N; Wang P
Vaccine; 2017 Oct; 35(43):5842-5849. PubMed ID: 28916248
[TBL] [Abstract][Full Text] [Related]
51. Genome engineering using CRISPR-Cas9 system.
Cong L; Zhang F
Methods Mol Biol; 2015; 1239():197-217. PubMed ID: 25408407
[TBL] [Abstract][Full Text] [Related]
52. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
53. CRISPR therapy towards an HIV cure.
Herrera-Carrillo E; Gao Z; Berkhout B
Brief Funct Genomics; 2020 May; 19(3):201-208. PubMed ID: 31711197
[TBL] [Abstract][Full Text] [Related]
54. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
[TBL] [Abstract][Full Text] [Related]
55. CRISPR/Cas9-mediated genome engineering: an adeno-associated viral (AAV) vector toolbox.
Senís E; Fatouros C; Große S; Wiedtke E; Niopek D; Mueller AK; Börner K; Grimm D
Biotechnol J; 2014 Nov; 9(11):1402-12. PubMed ID: 25186301
[TBL] [Abstract][Full Text] [Related]
56. Neoantigen Load, Antigen Presentation Machinery, and Immune Signatures Determine Prognosis in Clear Cell Renal Cell Carcinoma.
Matsushita H; Sato Y; Karasaki T; Nakagawa T; Kume H; Ogawa S; Homma Y; Kakimi K
Cancer Immunol Res; 2016 May; 4(5):463-71. PubMed ID: 26980598
[TBL] [Abstract][Full Text] [Related]
57. Antigenic targets for renal cell carcinoma immunotherapy.
Vieweg J; Jackson A
Expert Opin Biol Ther; 2004 Nov; 4(11):1791-801. PubMed ID: 15500407
[TBL] [Abstract][Full Text] [Related]
58. Genome-Wide CRISPR Screen Reveals Cancer Cell Resistance to NK Cells Induced by NK-Derived IFN-γ.
Zhuang X; Veltri DP; Long EO
Front Immunol; 2019; 10():2879. PubMed ID: 31921143
[TBL] [Abstract][Full Text] [Related]
59. Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics.
Breckpot K; Aerts JL; Thielemans K
Gene Ther; 2007 Jun; 14(11):847-62. PubMed ID: 17361214
[TBL] [Abstract][Full Text] [Related]
60. Advances in CRISPR-Cas9 genome engineering: lessons learned from RNA interference.
Barrangou R; Birmingham A; Wiemann S; Beijersbergen RL; Hornung V; Smith Av
Nucleic Acids Res; 2015 Apr; 43(7):3407-19. PubMed ID: 25800748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
